ReviewImmunity2018
Regulation and Function of the PD-L1 Checkpoint.
Review in Immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,321 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,321 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Efficacy and safety of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer: a meta-analysis.Frontiers in immunology · 2026Pooled it
- A Comprehensive Evaluation of the Effectiveness and Safety of Pembrolizumab for the Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.Current cancer drug targets · 2026Pooled it
- From mechanism to clinical: research evolution and hotspot analysis of CD276/B7-H3 in cancer immunotherapy.Frontiers in immunology · 2026Pooled it
- Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression.Frontiers in oncology · 2026Pooled it
- Immune checkpoint inhibitors-associated acute kidney injury: a systematic review and meta-analysis of incidence, kidney recovery, and recurrent risk.Cancer immunology, immunotherapy : CII · 2025Pooled it
- Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.Nature communications · 2025Trial
- Decoding the lncRNA landscape in bovine mastitis: insights into immune regulation and gene networks underlying host response.Journal of animal science and biotechnology · 2026Article
- NF-κB-driven immune checkpoint knockdown and cytokine expression in cancer cells for tumor immunotherapy.iScience · 2026Article
- Lactobacillus salivarius potentiates gastrointestinal cancer immunotherapy through its metabolite chenodeoxycholic acid.Cell reports. Medicine · 2026Article
- Unlocking the clock: a systematic review and meta-analysis on optimizing immune checkpoint inhibitor timing for advanced solid tumors.British journal of cancer · 2026Article
- Covalently PD-L1 Anchoring Drives Bispecific Nanostructure Assembly for Spatial Control of T Cell Recruitment and Activation.Angewandte Chemie (International ed. in English) · 2026Article
- Lactate-associated H3K18la upregulates RNF166 to promote immune evasion in hepatocellular carcinoma by remodeling c-Jun ubiquitination.Apoptosis : an international journal on programmed cell death · 2026Article
- Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential.Signal transduction and targeted therapy · 2026Review
- Ubiquitin-driven regulation of immune checkpoints in lung cancer: Mechanisms and therapeutic implications (Review).Experimental and therapeutic medicine · 2026Review
- Dissecting immunosuppressive microenvironment in chemotherapy-resistant colorectal cancer through single-cell transcriptomic analysis.Translational oncology · 2026Article
- Proximal Proteomics Reveals Potential Regulators of Programmed Death-Ligand 1 in Human Cancer.ACS omega · 2026Article
- Nanotechnology-based immunotherapy: integrating Artificial Intelligence (AI) with current strategies in combating brain cancer disease.Journal of the Egyptian National Cancer Institute · 2026Review
- Smyca-FOXM1 ribonucleoprotein complex promotes homologous recombination and tumor immune evasion to define a therapeutic target of triple-negative breast cancer.Journal of biomedical science · 2026Article
- Pan-Cancer Multi-Omics Analysis Reveals the Potential of ZDHHC16 in Tumor Progression and Immune Regulation.Chemical biology & drug design · 2026Article
- Design, synthesis and activity evaluation of tetrahydroisoquinoline-based programmed cell death ligand 1 inhibitors.Smart molecules : open access · 2026Article
1,261 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor immunity by counteracting T cell-activating signals. Antibody-based PD-1-PD-L1 inhibitors can induce durable tumor remissions in patients with diverse advanced cancers, and thus expression of PD-L1 on tumor cells and other cells in the tumor microenviroment is of major clinical relevance. Here we review the roles of the PD-1-PD-L1 axis in cancer, focusing on recent findings on the mechanisms that regulate PD-L1 expression at the transcriptional, posttranscriptional, and protein level. We place this knowledge in the context of observations in the clinic and discuss how it may inform the design of more precise and effective cancer immune checkpoint therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.